News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Apellis’ Empaveli® Gains FDA Approval for Broader Rare Kidney Disease Use
Penn spinout Apellis received FDA approval for an expanded label for Empaveli®.
Carisma Therapeutics Enters into Definitive Merger Agreement with OrthoCellix to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases
Carisma Therapeutics, co-founded by Saar Gill, MD, PhD, Associate Professor of Medicine at Penn Medicine, is merging with OrthoCellix.
Jim Wilson’s Gemma Biotherapeutics Enters into Partnership with the Abu Dhabi Department of Health and Purehealth to Advance Global Access to Gene Therapies for Rare Diseases
Gemma plans to establish manufacturing and research centers in Abu Dhabi.
Lilly Acquires Verve Therapeutics to Advance One-time Treatments for People with High Cardiovascular Risk
Eli Lilly has acquired Verve Therapeutics, a startup co-founded by Kiran Musunuru.
Penn Spinout Dispatch Bio Emerges from Stealth Mode with $216M in Funding
Dispatch Bio, co-founded by Carl June, MD, the Richard W. Vague Professor in Immunotherapy at Penn Medicine, is developing a universal cancer treatment for solid tumors.
Penn Spinout Interius Therapeutics To Be Acquired by Kite Therapeutics for $350M
Kite Therapeutics, a Gilead Company, has entered into a definitive agreement to acquire Interius Therapeutics .
Capstan Therapeutics Acquired by AbbVie for $2.1B
AbbVie acquired Capstan, including its lead asset CPTX2309.
September 2025 Bio/Medtech I-Corps Workshop
Penn I-Corps invites faculty, staff, postdocs, and students working on life science innovations to apply to the Special Bio/Medtech I-Corps Customer Discovery Workshop.
App that uses AI to boost caregiving for seniors wins PCI pitch competition at Philly Tech Week
PCI, Pennovation Works and Philadelphia Alliance for Capital & Technologies (PACT) hosted the “Innovate & Inspire: Research Panel & Pitch Competition” in May.